Economic Burden and Quality-of-Life Effects of Chronic Lymphocytic Leukemia: A Systematic Review of the Literature (Q35887697)

10 August 2017

title

Economic Burden and Quality-of-Life Effects of Chronic Lymphocytic Leukemia: A Systematic Review of the Literature (English)

1 reference

chronic lymphocytic leukemia

10 August 2017

0 references

1 reference

1 reference

Carl R Blankart

0 references

Tom Stargardt

1 reference

10 August 2017

Simon Frey

1 reference

10 August 2017

language of work or name

1 reference

6 January 2016

1 reference

10 August 2017

1 reference

10 August 2017

1 reference

10 August 2017

1 reference

10 August 2017

page(s)

479-498

1 reference

Cost-of-illness studies and cost-effectiveness analyses in eating disorders: a systematic review

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

Chronic lymphocytic leukemia: a clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

A clinical staging system for chronic lymphocytic leukemia: prognostic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 yr.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

Quality of life research in oncology. Past achievements and future priorities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

Chronic lymphocytic leukemia: economic burden and quality of life: literature review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

Economic assessment on the management of chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

Economic evaluations of leukemia: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

A process for systematically reviewing the literature: providing the research evidence for public health nursing interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

Modelling the cost effectiveness of rituximab in chronic lymphocytic leukaemia in first-line therapy and following relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

Cost of illness and economic burden of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

Impact of active surveillance, chlorambucil, and other therapy on health-related quality of life in patients with CLL/SLL in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

Patients' experience of chronic lymphocytic leukaemia: baseline health-related quality of life results from the LRF CLL4 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

Real-world costs of chronic lymphocytic leukaemia in the Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

Lifetime costs to Medicare of providing care to patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

Depression, anxiety and quality of life in a chronic lymphocytic leukemia cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

The DiSC assay. A cost-effective guide to treatment for chronic lymphocytic leukemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

Economic evaluation of third-line treatment with alemtuzumab for chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

Bendamustine versus chlorambucil for the first-line treatment of chronic lymphocytic leukemia in England and Wales: a cost-utility analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: lessons from the randomized European Society for Blood and Marrow Transplantation-Intergroup st

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

Evaluation of the Functional Assessment of Cancer Therapy-General (FACT-G) Spanish Version 4 in South America: classic psychometric and item response theory analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

Interpreting the significance of changes in health-related quality-of-life scores.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

Mapping the EORTC QLQ C-30 onto the EQ-5D instrument: the potential to estimate QALYs without generic preference data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

The health and economic consequences of osteopenia- and osteoporosis-attributable hip fractures in Germany: estimation for 2002 and projection until 2050.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

Generalized modeling approaches to risk adjustment of skewed outcomes data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0367-7

Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia

21 January 2018

1 reference

12 December 2020

Cost of illness of malignant lymphoma in Germany

1 reference

12 December 2020

Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia

1 reference

12 December 2020

Clinical staging of chronic lymphocytic leukemia

1 reference

12 December 2020

10.1007/S40273-015-0367-7

Identifiers

DOI

1 reference

10 August 2017

1 reference